http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant O
-
Merck Announces Second-Quarter 2026 Dividend
-
Merck starts phase 3 trial of KRAS G12C inhibitor with KEYTRUDA QLEX
-
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa
-
Merck to Complete Acquisition of Cidara Therapeutics
-
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
-
Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
-
Merck agrees with US government to expand medicine access and cut costs
-
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
-
Merck reports positive results for KEYTRUDA plus Padcev in bladder cancer
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients w
-
Merck gets EU committee backing for expanded WINREVAIR use in PAH
-
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
-
German court grants HALOZYME injunction against Merck's Keytruda SC
-
FDA conditionally approves Merck's cattle parasite treatment product
-
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
-
Merck receives FDA fast track for Alzheimer's drug MK-2214
-
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
-
Merck to Participate in the Citi 2025 Global Healthcare Conference
-
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
-
MERCK to present hematology pipeline data at ASH 2025 meeting
-
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
-
Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
-
FDA approves Merck's KEYTRUDA combinations for bladder cancer
-
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with C
-
Merck HIV drug combo meets phase 3 trial goals for treatment-naive patients
-
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Na
-
European Commission approves subcutaneous KEYTRUDA for all adult indications
-
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
-
Merck Announces First-Quarter 2026 Dividend
-
Merck's WINREVAIR meets primary endpoint in phase 2 heart failure study
-
Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserve
-
Merck to acquire Cidara for $9.2 billion to gain influenza drug
-
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
-
Merck to Participate in the Jefferies Global Healthcare Conference in London
-
Merck's experimental oral cholesterol drug shows promise in genetic disorder trial
-
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
-
Merck's oral PCSK9 inhibitor shows 55.8% cholesterol reduction
-
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
-
Merck receives $700 million from Blackstone for cancer drug development
-
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
-
Merck assumes full rights to MK-8690 drug after $150 million Falk deal
-
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
-
Merck and Eisai discontinue liver cancer trial after survival endpoint missed
-
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
-
European Commission approves Merck's KEYTRUDA for head and neck cancer treatment
-
European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CP
-
MilliporeSigma Partners with Promega to Advance 3-D Cell Drug Discovery Technologies
-
Merck drug combination meets cancer trial endpoint in kidney cancer study
-
Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Neph
